Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
boston top stories
crispr
5
×
life sciences
national blog main
gene editing
san francisco blog main
biotech
boston
deals
editas medicine
national top stories
san francisco top stories
allergan
cancer
clinical trials
cynthia collins
national
vc
abbvie
administration
alzheimer's
alzheimer's disease
amgen
bellicum pharmaceuticals
biogen
biomarin pharmaceutical
biontech
boulder/denver blog main
boulder/denver top stories
breakpoint therapeutics
car-t
celgene
celyad
crispr therapeutics
crispr-cas9
david walt
deafness
detroit blog main
detroit top stories
What
gene
5
×
editing
crispr
bio
editas
experimental
genetic
human
medicine
medicines
therapy
abbvie
allergan
alliance
becker
billions
biotech
blessing
bosley
cancer
cas
cells
ceo
check
clinical
create
cusp
defect
depart
diagnostic
diseases
dollars
drive
eaton
edited
exits
fears
fix
flag
guardian
Language
unset
Current search:
crispr
×
gene
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells